Reappraisal of role of angiotensin receptor blockers in cardiovascular protection

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 315-319

  Ram, C Venkata S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Angiotensin receptor blockers; Clinical trials; Hypertension; Outcomes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); HUMAN; REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 80053312799     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s15787     Document Type: Review

References (26)

1. Rosendorff C, Black HR, Cannon CP, et al; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761-2788.
2. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-2572.
3. Lip GY, Beevers DG. More evidence on blocking the renin-angiotensinaldosterone system in cardiovascular disease and the long-term treatment of hypertension: Data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2). J Hum Hypertens. 2003; 17:747-750.
4. Teo K, Yusuf S, Sleight P, et al; ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52-61.
5. Sleight P. The ONTARGET/TRANSCEND Trial Programme: Baseline data. Acta Diabetol. 2005;42 Suppl 1:S50-S56.
6. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86:747-803.
7. Atlas SA. The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13 Suppl B: 9-20.
8. Min LJ, Mogi M, Iwanami J, et al. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res. 2007;76:506-516.
9. Olsen MH, Wachtell K, Hermann KL, et al. Left ventricular hypertrophy is associated with reduced vasodilatory capacity in the brachial artery in patients with longstanding hypertension. A LIFE substudy. Blood Press. 2002;11:285-292.
10. Montalescot G, Collet JP. Preserving cardiac function in the hypertensive patient: Why renal parameters hold the key. Eur Heart J. 2005;26:2616-2622.
11. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
12. Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: Can we do better? Clin Ther. 2007;29:1803-1824.
13. Parving HH, Andersen S, Jacobsen P, et al. Angiotensin receptor blockers in diabetic nephropathy: Renal and cardiovascular end points. Semin Nephrol. 2004;24:147-157.
14. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003.
15. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:1004-1010.
16. Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitredipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218-1224.
17. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
18. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet. 2008;372:1174-1183.
19. Ogawa H, Kim-Mitsuyama S, Jinnouchi T, et al. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: A study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Hypertens Res. 2009;32: 575-580.
20. Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
21. Lewis E, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
22. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16-29.
23. Mann JF, Schmieder RE, McQueen MJ, et al; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.
24. Mann JF, Schmieder RE, Dyal L, et al; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. TRANSCEND Investigators. Effect of telmisartan on renal outcomes: A randomized trial. Ann Intern Med. 2009;151:1-10.
25. Imai E, Chan J, Ito S, Haneda M, Mankino H. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetic patients with overt nephropathy [Abstr SA764]. Presented at World Congress of Nephrology, May 23, 2009, Milan, Italy.
26. ORIENT: Olmesartan reducing incidence of end stage renal disease in diabetic nephropathy trial. Available at: www.clinicaltrials.gov/ ct2/show/NCT00141453?term=NCT00141453&rank=. Accessed December 9, 2009.